Clear Cell Renal Cell Carcinoma — Trials

Clear Cell Renal Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

247 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 114
Recruiting: 62
Ph III recruiting: 6
Growth YoY: −11.4%
Industry share: 30%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 44%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (39)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04810078	A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread(CheckMate-67T)	active not recruiting	Phase 3	681	Bristol-Myers SquibbINDUSTRY	17	Sep 22, 2026	clinicaltrials
NCT03793166	Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study	active not recruiting	Phase 3	1,175	National Cancer Institute (NCI)NIH